KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Raw Materials (2021 - 2025)

Rigel Pharmaceuticals has reported Raw Materials over the past 5 years, most recently at $7.0 million for Q3 2025.

  • Quarterly results put Raw Materials at $7.0 million for Q3 2025, up 342.96% from a year ago — trailing twelve months through Sep 2025 was $7.0 million (up 342.96% YoY), and the annual figure for FY2024 was $1.1 million, down 76.63%.
  • Raw Materials for Q3 2025 was $7.0 million at Rigel Pharmaceuticals, down from $9.6 million in the prior quarter.
  • Over the last five years, Raw Materials for RIGL hit a ceiling of $9.6 million in Q2 2025 and a floor of $1.1 million in Q4 2024.
  • Median Raw Materials over the past 5 years was $4.6 million (2022), compared with a mean of $4.6 million.
  • Biggest five-year swings in Raw Materials: crashed 76.63% in 2024 and later skyrocketed 348.76% in 2025.
  • Rigel Pharmaceuticals' Raw Materials stood at $5.1 million in 2021, then dropped by 11.42% to $4.6 million in 2022, then grew by 1.19% to $4.6 million in 2023, then crashed by 76.63% to $1.1 million in 2024, then soared by 545.31% to $7.0 million in 2025.
  • The last three reported values for Raw Materials were $7.0 million (Q3 2025), $9.6 million (Q2 2025), and $1.1 million (Q1 2025) per Business Quant data.